z-logo
open-access-imgOpen Access
Brain Alanine Formation as an Ammonia-Scavenging Pathway during Hyperammonemia: Effects of Glutamine Synthetase Inhibition in Rats and Astrocyte—Neuron Co-Cultures
Author(s) -
Sherry Dadsetan,
Eva Kukolj,
Lasse K. Bak,
Michael Sørensen,
Peter Ott,
Hendrik Vilstrup,
Arne Schousboe,
Susanne Keiding,
Helle S. Waagepetersen
Publication year - 2013
Publication title -
journal of cerebral blood flow and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.167
H-Index - 193
eISSN - 1559-7016
pISSN - 0271-678X
DOI - 10.1038/jcbfm.2013.73
Subject(s) - hyperammonemia , glutamine synthetase , glutamine , glutamate dehydrogenase , astrocyte , hepatic encephalopathy , in vivo , glutamate receptor , urea cycle , alanine , biochemistry , chemistry , medicine , cerebral edema , endocrinology , biology , pharmacology , amino acid , central nervous system , arginine , cirrhosis , receptor , microbiology and biotechnology
Hyperammonemia is a major etiological toxic factor in the development of hepatic encephalopathy. Brain ammonia detoxification occurs primarily in astrocytes by glutamine synthetase (GS), and it has been proposed that elevated glutamine levels during hyperammonemia lead to astrocyte swelling and cerebral edema. However, ammonia may also be detoxified by the concerted action of glutamate dehydrogenase (GDH) and alanine aminotransferase (ALAT) leading to trapping of ammonia in alanine, which in vivo likely leaves the brain. Our aim was to investigate whether the GS inhibitor methionine sulfoximine (MSO) enhances incorporation of 15 NH 4 + in alanine during acute hyperammonemia. We observed a fourfold increased amount of 15 NH 4 incorporation in brain alanine in rats treated with MSO. Furthermore, co-cultures of neurons and astrocytes exposed to 15 NH 4 Cl in the absence or presence of MSO demonstrated a dose-dependent incorporation of 15 NH 4 into alanine together with increased 15 N incorporation in glutamate. These findings provide evidence that ammonia is detoxified by the concerted action of GDH and ALAT both in vivo and in vitro, a mechanism that is accelerated in the presence of MSO thereby reducing the glutamine level in brain. Thus, GS could be a potential drug target in the treatment of hyperammonemia in patients with hepatic encephalopathy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom